Johnson & Johnson on Tuesday reported third-quarter earnings and revenue that beat expectations, boosted by higher sales of cancer and other prescription drugs, despite multimillion-dollar legal problems from talc and opioids.
Here’s what the company reported compared with Wall Street estimates, based on a survey of analysts by Refinitiv:
- Adjusted earnings per share: $2.12 versus $2.01 expected
- Revenue: $20.73 versus $20.07 billion expected
J&J also raised its full-year guidance and now sees earnings of $8.62 to $8.67 per share, with revenue in the range of $81.8 billion to $82.3 billion. Prior to the report, analysts were expecting full-year earnings guidance of $8.53 to $8.63 a share on revenue of $82.4 billion to $83.2 billion.
